User profiles for "author:S Mahner"
Sven MahnerUniversity of Munich Verified email at med.uni-muenchen.de Cited by 19780 |
[HTML][HTML] European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
Background Homologous recombination repair (HRR) enables fault-free repair of double-
stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade …
stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade …
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
Summary The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on
Clinical Research was held virtually in October, 2021, following published consensus …
Clinical Research was held virtually in October, 2021, following published consensus …
[HTML][HTML] Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer
Background Niraparib is an oral poly (adenosine diphosphate [ADP]–ribose) polymerase
(PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We …
(PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We …
[HTML][HTML] ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours …
…, F Joly, JW Kim, F Kridelka, D Lorusso, S Mahner… - Annals of …, 2019 - Elsevier
The development of guidelines recommendations is one of the core activities of the
European Society for Medical Oncology (ESMO) and European Society of Gynaecologial …
European Society for Medical Oncology (ESMO) and European Society of Gynaecologial …
Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix
…, J Ledermann, AN Viswanathan, S Mahner… - International Journal of …, 2014 - ijgc.bmj.com
Small cell carcinoma of the cervix (SCCC) is a rare histological entity of uterine cervical
cancer. Compared with other common histological types, squamous cell carcinoma or …
cancer. Compared with other common histological types, squamous cell carcinoma or …
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
…, J Špaček, P Vuylsteke, H Hirte, S Mahner… - The lancet …, 2015 - thelancet.com
Background The poly (ADP-ribose) polymerase inhibitor olaparib has shown antitumour
activity in patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer with …
activity in patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer with …
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label …
…, N Spirtos, N Concin, S Mahner… - The Lancet …, 2021 - thelancet.com
Background Few effective second-line treatments exist for women with recurrent or
metastatic cervical cancer. Accordingly, we aimed to evaluate the efficacy and safety of …
metastatic cervical cancer. Accordingly, we aimed to evaluate the efficacy and safety of …
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cervical cancer is the second most commonly diagnosed cancer and the third leading cause
of cancer death among females in less developed countries. There were an estimated 527 …
of cancer death among females in less developed countries. There were an estimated 527 …
[HTML][HTML] A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms
…, W Meier, D Cibula, A Mustea, S Mahner… - … England Journal of …, 2019 - Mass Medical Soc
Background Systematic pelvic and paraaortic lymphadenectomy has been widely used in
the surgical treatment of patients with advanced ovarian cancer, although supporting …
the surgical treatment of patients with advanced ovarian cancer, although supporting …
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO …
…, G Scambia, D Cibula, S Mahner… - International Journal of …, 2011 - ijgc.bmj.com
Purpose: The DESKTOP I trial proposed a score for the prediction of complete cytoreduction
in recurrent ovarian cancer. Resectability was assumed if 3 factors were present:(1) …
in recurrent ovarian cancer. Resectability was assumed if 3 factors were present:(1) …